Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.33 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750565 | 1.00 | CNR2 (0.33) | CNR2WEE1EGFRJAK2JAK3 | |
| SCHEMBL3745651 | 0.88 | ROCK2 (0.36) | CNR2WEE1EGFRJAK2JAK3 | |
| SCHEMBL3750045 | 0.81 | MAPT (0.39) | CNR2WEE1 | |
| SCHEMBL3751210 | 0.80 | CNR2 (0.35) | CNR2WEE1 | |
| SCHEMBL3744622 | 0.78 | CYP3A4 (0.37) | CNR2 | |
| SCHEMBL3748620 | 0.77 | CNR2 (0.33) | CNR2PLK4 | |
| SCHEMBL3741168 | 0.77 | MAPK10 (0.38) | CNR2 | |
| SCHEMBL3741163 | 0.77 | MAPK10 (0.38) | CNR2 | |
| SCHEMBL3746731 | 0.74 | CNR2 (0.37) | CNR2 | |
| SCHEMBL3746735 | 0.74 | CNR2 (0.37) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | CNR2 2755/4885WEE1 3597/4885EGFR 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.